Rampart Bioscience is thrilled to announce the successful completion of a funding round, raising an impressive $85 million to further advance its revolutionary approach to treating genetically driven diseases. This significant capital injection will enable Rampart to enhance its innovative non-viral DNA delivery system, a cornerstone of its mission to establish a new class of medicines that prioritize potency, durability, redosability, and safety. By integrating expertise from diverse scientific disciplines, including gene delivery, protein sciences, and clinical translation, Rampart aims to push the boundaries of what is possible in gene therapy and provide patients with more effective treatment options. The new funding will primarily be allocated towards accelerating clinical trials, optimizing their technology, and expanding their research capabilities to meet the urgent needs of patients grappling with genetic disorders. With the goal of reshaping the treatment landscape for those who desperately require better alternatives, Rampart Bioscience is poised to make a significant impact on the lives of countless individuals. The company’s dedication to innovating beyond the limitations of current therapies positions it as a leader in the biopharmaceutical industry, making strides towards delivering transformative therapies that can offer hope to patients worldwide. As we embark on this exciting journey, we extend our gratitude to our investors for their trust and commitment to our vision, which ultimately aims to bring forth effective solutions for complex genetic diseases.
Rampart Bioscience Secures $85 Million Funding to Revolutionize Gene Therapy Landscape
Recently funded · $85.0M Series aBiotechnology
Get the full Rampart Bioscience company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
Other recent Series a rounds
Companies that recently closed a Series a round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Aligned Marketplace | Series a | $20.0M | today |
| 2 |  Vals AI United States | Series a | $40.0M | today |
| 3 |
.png&w=3840&q=75)
